Custom Event Setup

×

Click on the elements you want to track as custom events. Selected elements will appear in the list below.

Selected Elements (0)

    BPC-157 and the Cardiovascular System: Research on Potential Cardioprotective Effects

    30.09.20267 min read
    BPC-157 and Cardiovascular Health: Research Overview

    BPC-157 is a synthetic peptide that has been investigated in experimental research for its potential effects on several biological systems, including the cardiovascular system.

    Preclinical studies, primarily conducted in animal models, have explored its possible influence on vascular function, blood flow, thrombosis, hyperkalemia, and certain cardiovascular disturbances.

    These findings have generated scientific interest in the potential cardioprotective mechanisms of BPC-157. However, the available evidence discussed in this article is largely based on experimental animal research, and further human clinical studies are required to establish its safety, effectiveness, and potential therapeutic relevance.

    Keywords: BPC-157, cardiovascular system, cardiovascular research, heart, blood vessels, vascular function, thrombosis, hyperkalemia, vasodilation, cardioprotection

    Abbreviations:
    ACE – angiotensin-converting enzyme
    ACh – acetylcholine
    ARB – angiotensin receptor blocker
    BPC – Body Protection Compound
    CVD – cardiovascular disease
    PE – phenylephrine

    Research Methods

    The studies discussed in this article were primarily conducted using laboratory animal models, including male and female rats.

    The research examined the potential effects of BPC-157 on various aspects of cardiovascular physiology, including vascular tone, blood flow, thrombosis, potassium-related disturbances, and experimentally induced cardiac effects.

    The Cardiovascular System

    Structure of the Cardiovascular System

    The cardiovascular system, also known as the circulatory system, consists primarily of the heart, arteries, veins, capillaries, and circulating blood.

    Together, these structures form a closed transport system that distributes oxygen, nutrients, hormones, and other essential substances throughout the body.

    Blood itself contains several important components, including plasma, erythrocytes (red blood cells), and leukocytes (white blood cells).

    Understanding the structure of the cardiovascular system also helps provide context for experimental research investigating how compounds such as BPC-157 may interact with vascular and circulatory processes.

    Functions of the Cardiovascular System

    The cardiovascular system performs several essential functions.

    The heart acts as the central pump, continuously circulating blood throughout the body.

    Arteries transport blood away from the heart toward tissues and organs, while veins return blood to the heart. Capillaries form small networks where oxygen, nutrients, metabolic products, and other substances can be exchanged between blood and surrounding tissues.

    Additional functions of the cardiovascular system include:

    • transport of hormones and nutrients,

    • delivery of oxygen to tissues,

    • removal of metabolic waste,

    • regulation of body temperature,

    • contribution to immune defence,

    • and maintenance of physiological pH balance.

    Cardiovascular Conditions Discussed in BPC-157 Research

    Cardiovascular diseases represent a significant global health concern.

    Several factors can influence cardiovascular risk, including diet, smoking, alcohol consumption, physical inactivity, age, genetic predisposition, metabolic disorders, and impaired glucose regulation.

    Lifestyle modifications such as balanced nutrition, regular physical activity, smoking cessation, and appropriate medical monitoring remain important components of cardiovascular risk management.

    Experimental research has also investigated BPC-157 in relation to several cardiovascular processes and conditions. However, these studies should be interpreted as preclinical research rather than established clinical treatment recommendations.

    BPC-157 and Arterial Hypertension Research

    Arterial hypertension is a major cardiovascular risk factor and can contribute to the development of additional cardiovascular complications when left uncontrolled.

    Lifestyle changes, dietary modifications, physical activity, and clinically approved medications remain standard approaches to blood-pressure management.

    Experimental studies have investigated whether BPC-157 may influence vascular tone.

    Experimental Research on Vasodilation

    One study evaluated the effects of BPC-157 on isolated aortic rings obtained from adult female rats.

    The aortic tissue was exposed to different concentrations of BPC-157 ranging from 0.1 to 100 μg/mL.

    Researchers reported concentration-dependent vasodilatory responses in aortic rings with intact endothelium.

    Reported vasodilation was approximately:

    • 16.5 ± 5.5% to 19.5 ± 3.0% at 0.1–1 μg/mL,

    • 28.3 ± 3.5% at 10 μg/mL,

    • and 48.3 ± 3.2% at 100 μg/mL.

    The researchers observed that the vascular response developed relatively quickly and remained sustained under the experimental conditions.

    These findings suggest that BPC-157 may interact with mechanisms involved in vascular tone. However, results obtained from isolated rat blood vessels cannot be directly interpreted as evidence of effectiveness in treating hypertension in humans.

    BPC-157 and Thrombosis Research

    Thrombosis occurs when a blood clot forms within a blood vessel and interferes with normal blood flow.

    Damage to vessel walls, altered blood flow, and changes in blood coagulation can contribute to thrombus formation.

    Clinically, thrombosis requires appropriate medical evaluation and established anticoagulant or other treatments depending on the specific condition.

    Experimental Study

    In one animal experiment, researchers investigated BPC-157 following complete occlusion of the superior mesenteric vein in young male rats.

    BPC-157 was administered at doses of 10 μg/kg and 10 ng/kg, while a control group received saline.

    Researchers monitored vascular congestion, venous insufficiency, and thrombus formation.

    Animals receiving BPC-157 showed differences in several vascular parameters compared with the control group, including reduced signs of congestion and thrombosis under the experimental conditions.

    These findings suggest a potential influence on vascular adaptation following experimentally induced venous occlusion.

    However, these results remain preclinical and do not establish BPC-157 as a treatment or preventive therapy for human thrombosis.

    BPC-157 and Hyperkalemia Research

    Hyperkalemia is a condition in which potassium levels in the blood become abnormally elevated.

    Severe hyperkalemia can interfere with normal cardiac electrical activity and may result in potentially serious arrhythmias.

    Established medical treatment may include intravenous calcium, glucose with insulin, beta-agonists, diuretics, dialysis, or other interventions depending on the cause and severity.

    Experimental Study

    Research involving male albino rats investigated whether BPC-157 could influence experimentally induced severe hyperkalemia.

    The animals received a high dose of potassium chloride to induce elevated potassium levels. BPC-157 was administered at doses of 10 ng/kg or 10 μg/kg either before or after potassium administration.

    Researchers reported that animals receiving BPC-157 demonstrated differences in the progression of experimentally induced hyperkalemia compared with untreated controls.

    The study suggested that BPC-157 may interact with physiological mechanisms involved in potassium-related cardiovascular disturbances.

    Nevertheless, these results come from an animal model and should not be interpreted as evidence that BPC-157 can treat hyperkalemia in humans.

    Hyperkalemia is a potentially serious medical condition requiring appropriate clinical assessment and treatment.

    Research on Potential Cardioprotective Effects of BPC-157

    Cardioprotection refers broadly to mechanisms or interventions that help reduce harmful effects on the heart and cardiovascular system.

    Established cardiovascular therapies may include ACE inhibitors, angiotensin receptor blockers, statins, antiplatelet medications, beta-blockers, and other treatments depending on the clinical condition.

    Experimental researchers have explored whether BPC-157 may influence some mechanisms associated with cardiovascular protection.

    BPC-157 and Experimentally Induced Bradycardia

    Bradycardia refers to a slower-than-normal heart rate.

    It may occur physiologically, particularly in trained athletes, or in association with certain medical conditions, medications, or abnormalities in cardiac conduction.

    One experimental study examined BPC-157 in rats experiencing lidocaine-induced seizures associated with bradycardia.

    Male albino rats received lidocaine to induce the experimental condition. BPC-157 at 10 μg/kg was administered either simultaneously with lidocaine or shortly afterward.

    Researchers reported a reduction in experimentally induced bradycardia when BPC-157 was administered after lidocaine and differences in bradycardia development when administered simultaneously.

    These findings indicate a potential interaction between BPC-157 and cardiovascular responses under this particular experimental model.

    Further research is required before conclusions can be drawn regarding clinical cardioprotective effects in humans.

    Current Research Perspective

    Experimental research on BPC-157 has explored several cardiovascular mechanisms, including:

    • vascular tone and vasodilation,

    • endothelial function,

    • responses to venous occlusion,

    • experimentally induced thrombosis,

    • potassium-related cardiovascular disturbances,

    • and experimentally induced bradycardia.

    The available findings are scientifically interesting and may help guide future investigation into the peptide's biological mechanisms.

    However, most of the evidence discussed here comes from laboratory and animal models.

    Animal studies are useful for understanding biological pathways, but their findings do not automatically demonstrate safety or effectiveness in humans.

    Summary

    The cardiovascular system plays an essential role in transporting oxygen, nutrients, hormones, and other substances throughout the body.

    BPC-157 has been investigated in experimental studies for its potential influence on vascular and cardiovascular processes.

    Preclinical research has reported effects involving vascular tone, venous occlusion, thrombosis-related mechanisms, experimentally induced hyperkalemia, and bradycardia.

    These results suggest that BPC-157 may interact with several biological pathways involved in cardiovascular function.

    At the same time, the research reviewed in this article is primarily experimental and animal-based. Further well-controlled human clinical research would be necessary to determine whether these findings have meaningful therapeutic relevance.

    The findings discussed here should therefore be considered part of ongoing scientific research rather than established evidence for the prevention or treatment of cardiovascular disease.

    Read also

    References

    1. Hsieh M.J., Liu C.H., Chen H.Y., et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of the Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10:17078. DOI: 10.1038/s41598-020-74022-y.

    2. Lozic M., Stambolija V., Krezic I., et al. In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro. 2020;2020:6805354. DOI: 10.1155/2020/6805354.

    3. Knezevic M., Gojkovic S., Krezic I., et al. Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats. Biomedicines. 2021;9(8):1029. DOI: 10.3390/biomedicines9081029.

    4. Barisic I., Balenovic D., Klicek R., et al. Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157. Regulatory Peptides. 2013;181:50–66. DOI: 10.1016/j.regpep.2012.12.007.

    This article is for educational purposes only and does not replace medical advice. The studies described concern the substances, not finished products.

    Keep reading

    More in Longevity & Health

    Formula finder

    Not sure where to start?

    3 quick questions. We’ll show you where to start and what it costs.

    Find yours in 30 seconds